MEI Pharma is a clinical-stage pharmaceutical company focused on developing cancer therapies. Co.'s drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway.
|
Free MEIP Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (3.00 out of 4) 27th percentile
(ranked lower than approx. 73% of all stocks covered)
Analysts' Target Price: MEIP Stock Forecast Based on Zacks ABR data; powered by Xignite |